Banco Santander Boosts Bristol Myers Squibb Stake

Banco Santander S.A. increases its holdings in the biopharmaceutical company by over 100%

Feb. 27, 2026 at 9:34am

Got story updates? Submit your updates here. ›

Banco Santander S.A. has significantly increased its stake in Bristol Myers Squibb Company (NYSE: BMY), boosting its holdings by 108.6% during the third quarter according to a recent SEC filing. The Spanish banking giant now owns over 500,000 shares of the biopharmaceutical company, valued at $22.7 million.

Why it matters

This substantial investment by a major global financial institution signals confidence in Bristol Myers Squibb's long-term growth prospects. As a leading biopharmaceutical company focused on developing innovative cancer and immune-mediated therapies, Bristol Myers Squibb's performance is closely watched by the investment community.

The details

Banco Santander reported owning 503,925 shares of Bristol Myers Squibb as of the end of the third quarter, up from 241,553 shares held at the end of the previous quarter. This represents a 108.6% increase in the bank's position in the biopharmaceutical firm. Bristol Myers Squibb's stock has seen strong performance recently, rising over 20% in the past six months.

  • Banco Santander increased its Bristol Myers Squibb holdings during the 3rd quarter of 2026.

The players

Banco Santander S.A.

A major Spanish banking group and one of the largest financial institutions in the world.

Bristol Myers Squibb Company

A global biopharmaceutical company headquartered in Princeton, New Jersey that is focused on discovering, developing and delivering medicines for serious diseases.

Got photos? Submit your photos here. ›

The takeaway

Banco Santander's substantial investment in Bristol Myers Squibb reflects the bank's confidence in the biopharmaceutical company's long-term growth potential, particularly in its pipeline of innovative cancer and immune-mediated therapies.